You are here

Investor Relations

Home

Jeffrey Leiden, Chairman, President and CEO

Date	Title and Summary
Toggle SummaryJul 17, 2019	Vertex to Announce Second-Quarter 2019 Financial Results on July 31 BOSTON --(BUSINESS WIRE)--Jul. 17, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2019 financial results on Wednesday, July 31, 2019 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET . Webcasts
Toggle SummaryJun 21, 2019	FDA Approves SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of CF in Children Ages 6-11 Years with Certain Mutations in the CFTR Gene -SYMDEKO is now approved for patients 6 years of age and older with two copies of the F508del mutation or one copy of a responsive mutation- -Vertex's third medicine approved to treat the underlying cause of CF in eligible patients in this age range- BOSTON --(BUSINESS WIRE)--Jun. General Business
Toggle SummaryJun 6, 2019	Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics -Provides Vertex with leading gene editing capabilities to develop novel therapies for Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1- -CRISPR to receive an upfront payment of $175 million , with potential for additional milestone and royalty payments- -Exonics to be acquired for an General Business